The launch of NMN clinical research in Japan

A historical milestone in NMN research

This archived article describes the start of an early human NMN study in Japan. Its references to a trial that has just begun describe that historical period, not a newly launched study in 2026.

The background was growing interest in the relationship between NAD+ metabolism, sirtuins and aging biology. Research by Shin-ichiro Imai, Leonard Guarente and other investigators helped establish the connection between NAD+ and the activity of the Sir2 family of proteins.

From molecular mechanisms to human investigation

Studies of calorie restriction, nutrient sensing and experimental organisms suggested several possible avenues for research. The archive lists diet, exercise, mTOR-related interventions, metformin and acarbose, NAD+ precursors and sirtuin-related approaches, mitochondrial interventions and other mechanisms.

These were different research directions, not a list of interchangeable, proven anti-aging treatments. Findings about a medicine in a disease context also cannot automatically be transferred to healthy people seeking longevity.

Why NMN was selected for study

NMN is an intermediate in the production of NAD+. Experimental studies had investigated changes in glucose metabolism, vascular and neurological function, and other physiological measures after altering NAD+ availability.

The next question was not simply whether the same biological story sounded plausible in people. Investigators needed to examine what happened after human administration, including tolerability and how the compound was metabolized.

The Japanese clinical research described in the archive

The original article describes collaboration involving Keio University School of Medicine in Tokyo and Washington University School of Medicine in St. Louis. The initial objectives included evaluating safety-related measures and the handling of NMN in the human body.

Such an early study is an important step, but it is not designed to establish that NMN reverses aging or treats all of the conditions discussed in animal experiments. Safety observations apply to the participants, dose, route and observation period studied.

Supplements and medicines are different development questions

The archive discusses the time and cost of pharmaceutical development and the potential role of supplement research. Cost alone does not determine whether a substance is an effective treatment or its legal classification. A supplement's availability is not evidence of therapeutic approval.

The lasting significance of this historical report is the transition from promising laboratory questions to direct human investigation. Later studies must be evaluated on their own methods and results.

Source identified in the archive: The first human clinical study for NMN has started in Japan. The original page displayed this Nature address but attached a different hyperlink; this English edition uses the address matching the named source.